CA3241913A1 - Polypeptide modulators - Google Patents
Polypeptide modulatorsInfo
- Publication number
- CA3241913A1 CA3241913A1 CA3241913A CA3241913A CA3241913A1 CA 3241913 A1 CA3241913 A1 CA 3241913A1 CA 3241913 A CA3241913 A CA 3241913A CA 3241913 A CA3241913 A CA 3241913A CA 3241913 A1 CA3241913 A1 CA 3241913A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- syndrome
- polypeptide
- autoimmune
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288330P | 2021-12-10 | 2021-12-10 | |
| US63/288,330 | 2021-12-10 | ||
| PCT/US2022/081186 WO2023108073A2 (en) | 2021-12-10 | 2022-12-08 | Polypeptide modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3241913A1 true CA3241913A1 (en) | 2023-06-15 |
Family
ID=86731448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3241913A Pending CA3241913A1 (en) | 2021-12-10 | 2022-12-08 | Polypeptide modulators |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250051419A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4444339A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024546654A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240118832A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118613277A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022405109A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3241913A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313360A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024006897A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023108073A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026519808A (ja) * | 2023-06-06 | 2026-06-18 | ジョージアミューン・インコーポレイテッド | 新規pd-l2変異体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000692A2 (en) * | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: pd-1 ligands and uses therefor |
| US10260038B2 (en) * | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| CN106794235A (zh) * | 2014-07-18 | 2017-05-31 | 阿德瓦希斯公司 | 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物 |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| US11219694B2 (en) * | 2015-09-24 | 2022-01-11 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
| CN118085109A (zh) * | 2016-08-11 | 2024-05-28 | 昆士兰医学研究所理事会 | 免疫调节化合物 |
| JP2020511144A (ja) * | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Pd−l2バリアント免疫調節タンパク質及びその使用 |
| WO2019060888A1 (en) * | 2017-09-25 | 2019-03-28 | New York University | HETÉRODIMÈRE-FC FUSION PROTEINS |
| US20210213063A1 (en) * | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| EP3908600A1 (en) * | 2019-01-11 | 2021-11-17 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Fusion protein with immunosuppressive activity |
-
2022
- 2022-12-08 MX MX2024006897A patent/MX2024006897A/es unknown
- 2022-12-08 WO PCT/US2022/081186 patent/WO2023108073A2/en not_active Ceased
- 2022-12-08 CA CA3241913A patent/CA3241913A1/en active Pending
- 2022-12-08 IL IL313360A patent/IL313360A/en unknown
- 2022-12-08 KR KR1020247022359A patent/KR20240118832A/ko active Pending
- 2022-12-08 JP JP2024533810A patent/JP2024546654A/ja active Pending
- 2022-12-08 US US18/718,397 patent/US20250051419A1/en active Pending
- 2022-12-08 EP EP22905373.1A patent/EP4444339A4/en active Pending
- 2022-12-08 AU AU2022405109A patent/AU2022405109A1/en active Pending
- 2022-12-08 CN CN202280090526.6A patent/CN118613277A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024546654A (ja) | 2024-12-26 |
| WO2023108073A3 (en) | 2023-10-19 |
| CN118613277A (zh) | 2024-09-06 |
| EP4444339A2 (en) | 2024-10-16 |
| KR20240118832A (ko) | 2024-08-05 |
| MX2024006897A (es) | 2024-06-20 |
| AU2022405109A1 (en) | 2024-06-27 |
| US20250051419A1 (en) | 2025-02-13 |
| WO2023108073A2 (en) | 2023-06-15 |
| IL313360A (en) | 2024-08-01 |
| EP4444339A4 (en) | 2026-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240325554A1 (en) | Methods for treating cancer | |
| JP7461350B2 (ja) | Arg1及び/又はarg2の阻害剤 | |
| KR102548798B1 (ko) | Pd-1/pd-l1 및 cd80/pd-l1 단백질/단백질 상호작용의 마크로시클릭 억제제 | |
| TWI812918B (zh) | IL-7Rαγc結合化合物 | |
| EP2927240A1 (en) | Compositions of pd-1 antagonists and methods of use | |
| JP7863349B2 (ja) | ガンマデルタt細胞を刺激するための方法及び組成物 | |
| CA3091805A1 (en) | Arginase inhibitors | |
| AU2018222735B2 (en) | Use of TGF alpha for the treatment of diseases and disorders | |
| US20200237822A1 (en) | Compositions and methods for stimulating natural killer cells | |
| WO2016115218A1 (en) | Antibody drug conjugates for the treatment of immune conditions | |
| US11999771B2 (en) | IL-7Rαγc ligand immunoglobulin fusion proteins | |
| US20250051419A1 (en) | Polypeptide modulators | |
| AU2024284838A1 (en) | Novel pd-l2 mutants | |
| HK40114371A (en) | Polypeptide modulators | |
| RU2792239C2 (ru) | Химерные белки на основе csf1r | |
| WO2023083439A1 (en) | Tlr7 agonist and combinations for cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED Effective date: 20240704 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: COVER PAGE PUBLISHED Effective date: 20240704 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241004 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241125 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241202 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241202 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250828 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251008 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251201 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251201 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20251210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251210 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20260622 Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20260622 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260622 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260622 |